前列腺癌周围脂肪组织影像表型、空间策略与多腔室整合的批判性综述
该批判性综述纳入113篇报告(其中63篇临床影像研究),系统评价前列腺周围脂肪组织(PPAT)在影像中的定义、采样与评估方式。PPAT影像应视为一组空间定义、任务特异的表型而非单一生物标志物,目前证据仅支持其作为已有临床和前列腺内影像信息的候选辅助,临床采纳需可重复定义、任务匹配的增量价值评估及独立外部验证。
要点
- PPAT影像策略以形态学/CT衰减为主(48篇),放射组学和界面建模证据较少。
- 仅19/63篇临床报告报告定量可重复性,仅2篇有独立外部评估且均非PPAT-only模型。
- PPAT是异质性肿瘤邻近腔室,但直接空间匹配的影像-组织验证仍不常见。
核心结论
- PPAT影像应被视为一组空间定义、任务特异的表型,而非单一生物标志物。
- 当前证据将PPAT定位为已有临床和前列腺内影像信息的候选辅助。
- 临床采纳需可重复定义与测量、任务匹配的增量价值评估、独立外部验证及决策影响的前瞻性证据。
研究设计与样本
- 结构化批判性综述与证据映射,检索PubMed/MEDLINE和Web of Science至2026年8月29日,辅以预设Google Scholar和引文检索。
- 两名评审独立筛选记录,正式证据集含113篇报告,其中63篇为临床影像报告。
- 报告按影像策略、空间靶点、临床任务、评估设计、可重复性、队列重叠和影像-组织对应关系进行映射。
关键影像表现/征象
- PPAT影像策略包括形态学/CT衰减(48篇)、组织特性/成分成像(4篇)、PPAT聚焦放射组学(4篇)和界面/多腔室建模(7篇)。
- 生物学和转化证据支持PPAT为异质性肿瘤邻近腔室,但直接空间匹配的影像-组织验证仍不常见。
- 临床证据涵盖活检前风险细化、升级或主动监测重分类、局部扩展与手术规划、预后、治疗相关结局及淋巴结和转移评估。
诊断标准与关键数值
- 定量可重复性仅在19/63篇临床报告中报告。
- 仅2篇报告接受独立外部评估,且均未评估PPAT-only模型。
临床应用与阅片要点
- 阅片和报告时应明确PPAT的空间定义和测量方法,避免将其作为单一生物标志物解读。
- 将PPAT影像信息作为已有临床和前列腺内影像信息的辅助,而非独立决策依据。
- 关注PPAT评估的任务特异性,针对不同临床任务选择匹配的影像策略和阈值。
局限性
- 多数报告缺乏独立评估,仅2篇有独立外部评估且均非PPAT-only模型。
- 定量可重复性报告不足,仅19/63篇临床报告报告。
- 直接空间匹配的影像-组织验证不常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To appraise how periprostatic adipose tissue (PPAT) is defined, sampled, and evaluated in prostate cancer imaging, with emphasis on spatial strategy, intended clinical use, evidence maturity, and imaging-tissue correspondence.
METHOD: We conducted a structured critical review with evidence mapping, supported by PubMed/MEDLINE and Web of Science searches through August 29, 2026, supplemented by prespecified Google Scholar and citation searches. Two reviewers independently screened records. Reports were mapped by imaging strategy, spatial target, clinical task, evaluation design, reproducibility, cohort overlap, and imaging-tissue correspondence.
RESULTS: The formal evidence set comprised 113 reports, including 63 clinical imaging reports. Strategies comprised morphometry / computed tomography (CT) attenuation (48 reports), tissue-property / compositional imaging (4), PPAT-focused radiomics (4), and interface / multicompartment modelling (7). Quantitative reproducibility was reported in 19/63 clinical reports. Only two reports underwent independent external evaluation, and neither evaluated a PPAT-only model. Biological and translational evidence supported PPAT as a heterogeneous tumour-adjacent compartment, whereas direct spatially matched imaging-tissue validation remained uncommon. Clinical evidence spanned prebiopsy risk refinement, upgrading or active-surveillance reclassification, local extension and surgical planning, prognosis, treatment-related outcomes, and nodal and metastatic assessment; most reports lacked independent evaluation.
CONCLUSIONS: PPAT imaging is best regarded as a set of spatially defined, task-specific phenotypes rather than a single biomarker. Current evidence positions PPAT as a candidate adjunct to established clinical and intraprostatic imaging information. Clinical adoption will require reproducible definitions and measurements, task-matched assessment of incremental value, independent external evaluation, and prospective evidence of decision impact.
引用
- Huang J, Zhang Y, Yang O, et al. Periprostatic adipose tissue imaging in prostate cancer: Imaging phenotypes, task-specific spatial strategies, and multicompartment integration-a critical review. Eur J Radiol. 2026. PMID: 42874220. doi:10.1016/j.ejrad.2026.113296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。